Ghafoor Naeem Abdul, Kırboğa Kevser Kübra, Baysal Ömür, Süzek Barış Ethem, Silme Ragıp Soner
Department of Molecular Biology and Genetics, Faculty of Science, Muğla Sıtkı Koçman University, Kötekli, 48121, Muğla, Turkey.
Bioengineering Department, Bilecik Seyh Edebali University, 11230, Bilecik, Turkey.
Mol Divers. 2024 Aug;28(4):1869-1888. doi: 10.1007/s11030-023-10707-6. Epub 2023 Aug 10.
HIV-1 is a deadly virus that affects millions of people worldwide. In this study, we aimed to inhibit viral replication by targeting one of the HIV-1 proteins and identifying a new drug candidate. We used data mining and molecular dynamics methods on HIV-1 genomes. Based on MAUVE analysis, we selected the RNase H activity of the reverse transcriptase (R.T) enzyme as a potential target due to its low mutation rate and high conservation level. We screened about 94,000 small molecule inhibitors by virtual screening. We validated the hit compounds' stability and binding free energy through molecular dynamics simulations and MM/PBSA. Phomoarcherin B, known for its anticancer properties, emerged as the best candidate and showed potential as an HIV-1 reverse transcriptase RNase H activity inhibitor. This study presents a new target and drug candidate for HIV-1 treatment. However, in vitro and in vivo tests are required. Also, the effect of RNase H activity on viral replication and the interaction of Phomoarcherin B with other HIV-1 proteins should be investigated.
HIV-1是一种致命病毒,影响着全球数百万人。在本研究中,我们旨在通过靶向HIV-1蛋白之一并鉴定一种新的候选药物来抑制病毒复制。我们对HIV-1基因组使用了数据挖掘和分子动力学方法。基于MAUVE分析,由于逆转录酶(R.T)酶的核糖核酸酶H活性突变率低且保守水平高,我们将其选为潜在靶点。我们通过虚拟筛选对约94,000种小分子抑制剂进行了筛选。我们通过分子动力学模拟和MM/PBSA验证了命中化合物的稳定性和结合自由能。以其抗癌特性而闻名的Phomoarcherin B成为最佳候选物,并显示出作为HIV-1逆转录酶核糖核酸酶H活性抑制剂的潜力。本研究提出了一种用于HIV-1治疗的新靶点和候选药物。然而,还需要进行体外和体内试验。此外,应研究核糖核酸酶H活性对病毒复制的影响以及Phomoarcherin B与其他HIV-1蛋白的相互作用。